Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
November 18, 2024 11:15 ET | Source: BridgeBio Pharma, Inc. - Acoramidis…
Trump Wins the U.S. Election: Cryptocurrency Staking Market Primed for Significant Growth with STAKING AI at the Helm
Los Angeles, CA, Nov. 08, 2024 (GLOBE NEWSWIRE) -- With the announcement…
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase…